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Abstract 
Leishmaniasis is a clinically heterogeneous syndrome caused by intracellular protozoan parasites of the genus Leishmania. The clinical 
spectrum of leishmaniasis encompasses subclinical ( not apparent), localized (skin lesion), and disseminated (cutaneous, mucocutaneous, and 
visceral) infection. This spectrum of manifestations depends on the immune status of the host, on the parasite, and on immunoinflammatory 
responses. Visceral leishmaniasis causes high morbidity and mortality in the developing world. Reliable laboratory methods become 
mandatory for accurate diagnosis, especially in immunocompromised patients such as those infected with HIV. In this article, we review the 
current state of the diagnostic tools for leishmaniasis, especially  the serological test. 
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Introduction 
The term leishmaniasis refers to a group of vector-
borne diseases caused by obligate intracellular 
protozoan parasites of the genus Leishmania, 
belonging to the family Trypanasomatidae, order 
Kinetoplastidia. Natural transmission of the parasite 
occurs primarily via the bite of infected female 
sandflies of the genus Phlebotomous in the Old World 
and Lutzomyia in the New World. The disease can also 
be transmitted by shared syringes among intravenous 
drug abusers [1], by blood transfusion [2], by venereal 
infections [3,4], and congenitally from mother to 
infant [5]. However, these modes of transmission are 
very rare compared with vector-borne transmission. In 
a domestic environment, dogs are the most important 
reservoirs, maintaining the parasite endemic focus. 
Rodents also play a role as Leishmania reservoirs [6-
8].  
Leishmaniasis occurs in three clinical forms: (i) 
cutaneous leishmaniasis (CL), which is caused by L. 
major, L. tropica, L. aethiopica (Old World CL), L. 
infantun, L. chagasi (Mediterranean and Caspian Sea 
region CL), L. amazonensis, L. mexicana, L. 
braziliensis, L. panamesis, L. peruviana, and L. 
guayanensis (New World CL); (ii) mucocutaneous 
leishmaniasis (MCL) or espundia, which is caused by 
L. brazilensis, L. panamensis, L. guyanensis in the 
New World and is occasionally encountered in the Old 
World, caused by L. infantum and L. donovani; (iii) 
visceral leishmaniasis (VL), which is caused by 
species of the L. donovani complex that consist mainly 
of L. infantum, L. donovani, and L. chagasi. LV is also 
known as kala-azar, black fever, and Dumdum fever. 
There is a fourth form, known as diffuse cutaneous 
leishmaniasis (DCL), which is caused by L. 
amazonensis and L. aethiopica [9]. 
CL is the most prevalent form and manifests as 
skin lesions that can heal spontaneously. VL is the 
most severe form of the disease and, left untreated, is 
usually fatal. Post-kala-azar dermal leishmaniasis 
(PKDL) is a complication of LV, characterized by a 
macular, maculo-papular, or nodular rash on the face, 
torso, or other part of the body. It occurs mainly in 
East Africa and the Indian subcontinent, behaving as 
the major reservoir of the parasite in areas of 
anthroponotic transmission [10]. The mucocutaneous 
form causes partial or total mutilation of mucous 
membranes in the nose, mouth, and throat.  
Leishmania infections are worldwide in 
distribution; they have been reported in 98 countries 
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on all continents. The disease is endemic in tropical 
and subtropical regions. There are an estimated 1.3 
million new cases worldwide annually, of which 1 
million are CL or MCL and another 300,000 cases are 
VL, with approximately 200 million people at risk of 
infection [11]. Of the 1.3 million estimated cases, only 
600,000 are actually reported [12]. 
VL occurs mainly (90% of cases) in Bangladesh, 
Brazil, Ethiopia, India, Nepal, South Sudan, and 
Sudan. The governments of these countries have 
committed to eliminate VL by 2015 and aim to reduce 
the incidence of VL to 1 per 10,000 population in 
endemic districts [13]. VL is an important 
opportunistic infection in AIDS patients; in countries 
where there is poor access to antiretroviral therapy, the 
prevalence of visceral disease is rising [14]. These 
alarming facts have been attributed in part to the 
absence of an effective VL vaccine [15]. 
CL is found primarily in Afghanistan, Algeria, 
Brazil, Colombia, the Islamic Republic of Iran, 
Pakistan, Peru, Saudi Arabia, the Syrian Arab 
Republic, and Tunisia. Almost 90% of MCL cases 
occur in Brazil, Peru, and Bolivia. The health burden 
of CL in these countries remains largely unknown, 
partly because those who are most affected live in 
remote areas and often do not seek medical attention 
[12,15]. 
Control of leishmaniasis requires a combination of 
intervention strategies; early diagnosis and treatment is 
an important aspect. In VL, diagnosis is made by 
combining clinical signs with parasitological or 
serological tests (rapid diagnostic tests and others). In 
addition, an accurate diagnostic test that can identify 
active VL versus asymptomatic disease remains a key 
component of measures that aim to control this serious 
disease [16]. In CL and MCL, serological tests have 
limited value. Table 1 presents a summary of all the 
serological and antigen detection techniques 
commonly used for leishmaniasis diagnosis.  
 
Diagnosis of cutaneous and mucocutaneous 
leishmaniasis 
In the laboratory, diagnosis is made 
microscopically by direct identification of amastigotes 
in Giemsa-stained lesion smears of biopsies, scrapings, 
or impression smears. Amastigotes are observed as 
round or oval bodies, 2–4 μm in diameter, with 
characteristic nuclei and kinetoplasts. The material 
from the ulcer base usually has the highest yield; 
however, other authors have not found significant 
differences in the diagnostic outcomes when smears or 
culture samples are taken from the center or the border 
of the ulcer or from an incision made tangential from 
the ulcer [17,18]. Conventionally, three to five 
aspirates from different lesions or portions of lesions 
are dissected. The first samples should be used for 
microscopy and the last for culture to minimize the 
risk of contamination [19]. A combination of 
microscopy and culture increases diagnostic sensitivity 
to more than 85% [18,20]. 
Antileishmanial antibodies can be detected by 
serological tests; however, these are not the usual 
methods, because antibodies tend to be undetectable or 
present in low titers due to poor humoral response [21-
23]. 
Culture and DNA detection by PCR are sensitive 
but are not currently practical in developing countries. 
 
Diagnosis of visceral leishmaniasis 
In developing countries where the disease is not 
prevalent, the existence of laboratory facilities enables 
an adequate and efficient follow-up of the disease. 
However, in developing countries with large numbers 
of patients in rural areas, simple diagnostic tools are 
necessary for field use [24]. Laboratory diagnosis of 
VL includes microscopic observation and culture from 
adequate samples, antigen detection, serological tests, 
and detection of parasite DNA. 
 
Culture and microscopic observation 
Definitive VL diagnosis is supported by direct 
demonstration of parasites in clinical specimens and 
specific molecular methods [25-27]. The commonly 
used samples are splenic or bone marrow aspirates. 
The presence of amastigotes can also be determined in 
other samples such as liver biopsies, lymph nodes, and 
buffy coats of peripheral blood. The sensitivity of the 
bone marrow stained with Giemsa is about 60% to 
85%. In splenic aspirates, the sensitivity is higher 
(93%) [28], but sampling is associated with a risk of 
fatal hemorrhage in inexperienced hands. To increase 
the sensitivity, fluorescent dye-conjugated antibodies 
can be used [29]. The sensitivity in peripheral blood 
smears is low, especially in individuals with low 
parasitemia. In addition, results are dependent on 
technical expertise and the quality of prepared slides. 
Culture of the parasite can improve diagnostic 
sensitivity, but is tedious, time-consuming, and 
expensive, and thus seldom used for clinical diagnosis. 
There are new culture methods that improve 
sensitivity, such as the micro-culture method (MCM); 
recent modifications of this method involve using the 
buffy coat and peripheral blood mononuclear cells 
[30,31].  
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The culture media used may be biphasic and may 
include Novy-MacNeal-Nicolle medium and Tobie’s 
medium (conversion of amastigotes to promastigotes 
and monophasic medium), Schneider's insect medium, 
M199, and Grace's insect medium (amplifying parasite 
number) [29]. 
 
Antigen detection in urine 
Several studies have demonstrated leishmanial 
antigen in the urine of VL patients. In 1995, De 
Colmenares et al. reported two polypeptide fractions 
of 72–75 kDa and 123 kDa in the urine of kala-azar 
patients [32]. In 2002, Sarkari et al. described a 
urinary 5–20 kDa carbohydrate-based, heat stable 
antigen of VL patients [33]. A latex agglutination test 
(KAtex, Kalon Biological, UK) for detection of this 
antigen in urine samples was evaluated using samples 
from confirmed cases and controls from endemic and 
non-endemic regions. This test showed good 
specificity (82% to 100%), but had low to moderate 
sensitivity that ranged from 47% to 95% [34-38]. 
Nowadays, this method is useful for the diagnosis of 
disease in cases with deficient antibody production. In 
this respect, this method has reported 100% sensitivity 
and 96% specificity in immunocompromised patients 
[39]. In another study, 87% specificity and 85% 
sensitivity were obtained for primary VL in HIV-co-
infected patients, and the method had predictive 
capabilities in the follow-up of treatment and detection 
of subclinical infection in Leishmania/HIV co-infected 
Table 1. Serological and antigen detection techniques commonly used for leishmaniasis diagnosis 





Advantages Disadvantages References 
Antibody detection      
IFA test 87–100 77–100 
Positive in the early stages 
of infection and 
undetectable six to nine 
months after cure. 
Requires sophisticated 
laboratory. No application in 
the field. 
41,42,43 
ELISA   
Can be used to screen a 
large scale of epidemiologic 
studies. 
Sensitivity and specificity is 
greatly influenced by the 
antigen used. 
Requires skilled personnel, 
sophisticated equipment, and 
electricity.  
 
CSA as antigen 80–100 84–95   45,46,47 
with fucose-mannose 
ligand 
95–100 95   53 
rK39 as antigen 75–98 79–89   58,59 
Western blot 90–98 98–100 
Provides detailed antibody 
responses to various 
leishmanial antigens. 
Time consuming, technically 
cumbersome, and expensive. 
69, 70, 71, 72, 
73 
DAT 85–100 91–100 
Rapid test, applicable in the 
field. 
Limited to use in regions of 
endemicity. 
Long incubation time is 
needed.  
Unavailability of commercial 
source of the postive antigen 
and fragility of is aqueous 
form. 
74,75,76,77,79 
IC test with rK39 90–100 93–100 
Inexpensive, rapid, simple, 
and can be performed by 
untrained person. 
 84,85,86,88 
Antigen detection      
Latex agglutination 
test in urine (KAtex) 
79–100 60–100 
Simple, easy performing. 




Difficult to distinguish 
weakly positive from 
negative results and the urine 
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cases [40]. Another urinary leishmanial antigen, a low-
molecular weight, heat-stable carbohydrate has been 
detected in the urine of VL patients by an 
agglutination test with 60% to 71% sensitivity and 
79% to 94% specificity [41]. In summary, the latex 
agglutination test is simple, easy to perform, 
inexpensive, rapid, and can be used as a screening test. 
Efforts are being made to improve the performance of 
this technique, because it promises to be a test of cure 
in populations of developing areas [28]. 
 
Serological diagnosis 
Specific serological diagnosis is based on the 
presence of a specific humoral response. Current 
serological tests are based on four formats: indirect 
fluorescent antibody (IFA), enzyme-linked 
immunosorbent assay (ELISA), western blot, and 
direct agglutination test (DAT). The sensitivity 
depends upon the assay and its methodology, but the 
specificity depends on the antigen rather than the 
serological format used. 
It has been noted that all antibody detection tests 
share the same drawbacks; the antibodies remain 
positive for many months after the patient has been 
cured and do not differentiate between current and past 
infection. In endemic regions, asymptomatically 
infected persons can also be positive in these tests.   
 
Indirect fluorescent antibody (IFA) test 
The IFA test shows acceptable sensitivity (87%–
100%) and specificity (77%–100%) [41,42]. 
Promastigote forms should be the antigens of choice 
for diagnosis of visceral leishmaniasis by the IFA test 
because they minimize cross-reactivity with 
trypanosomal sera [43]. The antibody response is 
detectable very early in infection and becomes 
undetectable six to nine months after cure; hence, if 
the antibodies persist in low titers, it is a good 
indication of a probable relapse [44]. The need for a 
sophisticated laboratory with a fluorescence 
microscope restricts use of the IFA test to reference 
laboratories. 
 
Enzyme-linked immunosorbent assay (ELISA) 
ELISA is the preferred laboratory test for 
serodiagnosis of VL. The technique is highly sensitive, 
but its specificity depends upon the antigen used. 
Moreover, this assay can be performed easily and is 
adaptable for use with several antigenic molecules. 
One of the antigens used in the ELISA test is a 
crude soluble promastigote antigen (CSA) that is 
obtained by freezing and thawing live promastigotes. 
The sensitivity of ELISA using CSA ranges from 80% 
to 100%, and specificity ranges from 84% to 95% 
[45,46]. Cross-reactivity with sera from patients with 
tuberculosis, trypanosomiasis, and toxoplasmosis has 
been reported [47-51]. When selective antigenic 
molecules were used (with molecular weights of 116 
kDa, 72 kDa, and 66 kDa), the specificity approached 
100%, while the sensitivity was very low (37%) 
[31,52]. Other purified antigens used were a 36-kDa 
glycoprotein [53], metabolic antigens released by L. 
donovani [54], and A2 proteins implicated in the 
development of visceral disease [55-57].  
A conserved portion of a kinesin-related protein 
recombinant antigen from a cloned protein of L. 
chagasi, called rK39, has been reported to be highly 
reactive to sera from human and canine VL cases 
when run in an ELISA format [58,59]. Using this 
recombinant antigen, 99% specificity and sensitivity 
were reported in immunocompetent patients with 
clinical VL. In India, this antigen was reported with a 
sensitivity of 98% and a specificity of 89% [60]; 
however, a report from Sudan and other countries 
revealed that this antigen showed low sensitivity 
(75%) and specificity (70%) [61]. In HIV-positive 
patients, rK39-ELISA showed higher sensitivity (82%) 
than the IFA test (54%), with higher predictive value 
for detecting VL [62]. With successful therapy, 
antibody titers declined steeply at the end of treatment 
and during follow-up; in contrast, patients who 
relapsed showed increased titers of antibodies to rK39. 
This suggests the possible application of rK39-ELISA 
in monitoring drug therapy and detecting relapse of 
VL [51]. 
In another study, two hydrophilic antigens of 
Leishmania chagasi were used (rk9 and rk26), leading 
to an increase in the list of available antigens for 
serodiagnosis of VL [63]. Another kinesin 
recombinant related protein used in ELISA assay is 
rKE16. The use of this antigen for VL diagnosis has 
been very sensitive and specific as rK39 when tested 
in patients from China, Pakistan, and Turkey [64]. 
Another new assay, based on the detection of the 
K28 fusion protein in studies performed in Sudan and 
Bangladesh with 96% sensitivity in Sudan and 98% in 
Bangladesh, has been developed [65]. Moreover, heat 
shock proteins HPS70 or histones proteins H2A, H2B, 
H3, and H4 may have potential use for serodiagnosis 
of VL [66,67]; furthermore, lipid-binding proteins 
(LBPs) as antigens have shown high levels of 
sensitivity and an absence of cross-reactions with the 
sera of patients with other diseases [69].  The ELISA 
test, due to the requirement of skilled personnel, 
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sophisticated equipment, and electricity, is not used in 
endemic regions for the diagnosis of VL. 
 
Immunoblotting (western blot) 
For this type of testing, promastigotes are cultured 
to log phase, lysed, and the proteins are separated on 
SDS-PAGE. The separated proteins are 
electrotransferred onto a nitrocellulose membrane and 
probed with serum from the patient. The western blot 
technique provides detailed antibody responses to 
various leishmanial antigens [69,70], and has been 
found to be more sensitive than the IFA test and 
ELISA, especially in co-infected HIV patients with 
VL [71-73], but the drawbacks of the technique 
(equipment and time requirements, cumbersomeness, 
and cost) limit its use to research laboratories. 
 
Direct agglutination test (DAT) 
The DAT is based on direct agglutination of 
Leishmania promastigotes that react specifically with 
anti-Leishmania antibodies in the serum specimen, 
resulting in agglutination of the promastigotes. Whole, 
trypsinized, coomassie-stained promastigotes can be 
used either as a suspension or in freeze-dried form that 
can be stored at room temperature for at least two 
years, facilitating its use in the field [74,75].  
Chappuis et al. [76], in a meta-analysis that 
included thirty studies evaluating DAT, found that the 
DAT had sensitivity and specificity estimates of 
94.8% (95% confidence intervals [CI], 92.7–96.4) and 
97.1% (95% CI, 93.9–98.7), respectively. Moreover, 
in settings where parasitological confirmation is not 
feasible, the freeze-dried DAT together with classical 
clinical features of VL can be used for diagnosis at a 
cut-off for positive DAT, which is 1:12,800 as in 
endemic areas. The DAT is simpler than many other 
tests but presents severe problems in terms of 
reproducibility of results, which depends on antigen 
elaboration [77]. A new antigen elaboration method, 
the EasyDAT described in 2003, shows the same 
sensitivity, specificity, and durability as the traditional 
DAT antigen method but offers the additional 
advantages of cost reduction and standardization [78]. 
Although the DAT for the serodiagnosis of 
visceral leishmaniasis has high sensitivity and 
specificity, it still has some limitations; among these 
are the relative long incubation time (18 hours) and the 
serial dilutions of the samples that must be made. In 
order to circumvent these problems, Schoone et al. in 
2001 [79] developed a fast agglutination screening test 
(FAST). The FAST utilizes only one serum dilution 
(qualitative result) and requires three hours of 
incubation. This makes the test very suitable for the 
screening of large populations. The sensitivity and 
specificity of FAST were found to be 91.1%–95.4% 
and 70.5%–88.5%, respectively [80,81].   
Anti-Leishmania antibodies may persist for years 
as a result of previous VL infection, so titers measured 
by DAT may remain positive for up to five years after 
recovery in > 50% of VL patients, which may limit the 
DAT’s widespread applicability in regions of 
endemicity.  Although the DAT is the first real field 
test, it remains the serological test of choice as well as 
the first antibody detection test for VL used in field 
settings, particularly in many developing countries and 
in Leishmania/HIV co-infections [73,82,83]. 
 
Immunochromatographic assay (IC) 
The immunochromatographic test using rK39 
antigen (39 amino-acid-repeat recombinant 
leishmanial antigen from L. chagasi) has become 
popular in recent years. It is a qualitative membrane-
based immunoassay with nitrocellulose strips 
impregnated with recombinant K39 Leishmania 
antigen. A drop of blood or serum is smeared over the 
pad of the strips and dipped in a small amount of 
buffer; the results are ready within a few minutes.  
In clinical cases of VL, the rK39 IC showed 
variation in the sensitivity and specificity among 
different populations. The rK39 IC showed 100% 
sensitivity and 93%–98% specificity in India [84,85], 
90% sensitivity and 100% specificity in Brazil [86], 
and 100% sensitivity and specificity in the 
Mediterranean area [87]. In other reports in southern 
Europe, the rK39 IC test was positive in only 71.4% of 
the cases of VL [88]; in Sudan, rK39 IC showed a 
sensitivity of 67% [61]. These differences in 
sensitivity may be due to differences in the antibody 
responses observed in different ethnic groups. The 
rK39 IC assay has proven to be versatile in predicting 
acute infection, and it is the only available format for 
diagnosis of VL with acceptable sensitivity and 
specificity levels. It is also easy to use in the field, 
rapid (15–20 minutes), cheap, and gives reproducible 
results. Like the DAT assay, IC is positive in a 
significant proportion of healthy individuals in 
endemic regions and for long periods after cure; 
hence, this limits its usefulness in persons with a 
previous history of VL who present with recurrence of 
fever and splenomegaly, as these tests cannot 
discriminate between a case of VL relapse and other 
pathologies. 
 
Elmahallawy et al. – Diagnosis of leishmaniasis               J Infect Dev Ctries 2014; 8(8):961-972. 
966 
Latex agglutination test (LAT) 
The LAT is one of the recently developed rapid 
diagnostic tests for the rapid detection of anti-
Leishmania antibodies against the A2 antigen derived 
from the amastigote form as well as those against 
crude antigens derived from the promastigote form of 
an Iranian strain of L. infantum. In a comparative 
study with the DAT, the sensitivity of tested human 
sera from DAT-confirmed patients yielded 88.4% 
sensitivity, while the specificity was 93.5% on A2-
LAT amastigote, with a higher degree of similarity in 
accuracy to the DAT [89,90]. 
 
Molecular methods: polymerase chain reaction (PCR) 
Although different molecular methods have 
successively been evaluated for leishmaniasis 
diagnosis, PCR-based assays are the main molecular 
diagnostic tools, especially in immunosupressed 
patients [91-94].  
PCR protocols to detect Leishmania DNA in VL 
diagnosis have used a variety of samples, including 
spleen, lymph node, and bone marrow aspirates, whole 
blood, and buffy coat [92,95-101].  
There are different target sequences used, which 
include ribosomal RNA genes, kinetoplast DNA 
(kDNA), miniexon-derived RNA (medRNA), and the 
β-tubulina gene region [103]. 
Many PCR-based methods for diagnosis of VL 
have been described with different specificities and 
sensitivities; PCR assay sensitivity depends on the 
sample used. Sensitivity is highest (near 100%) in 
spleen or bone marrow [93,97,102] samples. The ideal 
sample is peripheral blood due to its non-invasive 
character. Using peripheral blood, the sensitivity 
ranges described vary from 70% to 100% 
[93,102,103].   
A comparative clinical study between conventional 
microbiologic techniques and a leishmania species-
specific PCR assay in HIV-co-infected and HIV-
uninfected patients has shown the sensitivity of the 
leishmania species-specific PCR to be 95.7% for bone 
marrow and 98.5% for peripheral blood samples; the 
sensitivity in HIV-co-infected and non-HIV-co-
infected adults  was 100% [94]. 
A PCR-ELISA was used to diagnose VL in HIV-
negative patients; peripheral blood was used and 
yielded a high sensitivity [104]. A similar PCR-based 
technique was applied in the diagnosis of VL in HIV 
patients, with good results [28].  
Recently, an evaluation of an 
oligochromatography-PCR for diagnosis of VL, 
cutaneous leishmaniasis (CL), and post kala-azar 
dermal leishmaniasis (PKDL), showed a high 
sensitivity (> 95%) on lymph, blood, and bone marrow 
samples from confirmed VL patients [105]. 
Another interesting approach is a rapid fluorogenic 
PCR technique. Wortmann et al. used a fluorescent 
DNA probe for a conserved rRNA gene that is 
amplified using flanking primers; this technique using 
clinical samples showed great sensitivity and 
specificity [98]. The real-time PCR has the advantage 
of being quantitative, which could be useful in the 
follow-up of treatment, allowing for the assessment of 
the parasite burden [106,107].  
However, PCR techniques remain complex and 
expensive, and in most VL-endemic countries, they 
are restricted to a few teaching hospitals and research 
centers. 
 
Diagnosis of VL-HIV co-infection 
According to the World Health Organization 
(WHO) [108], an estimated 35 million people 
worldwide are living with HIV. Immunosuppression 
may reactivate latent Leishmania infection in 
asymptomatic patients and among HIV/AIDS patients. 
It is known that Leishmania has emerged as an 
opportunistic disease among HIV patients in endemic 
areas [109-112]. Moreover, it has been noted that the 
risks of clinical VL in HIV patients increased by 100 
to 1,000) [111]. Although cases of co-infection have 
so far been reported in 33 countries worldwide, most 
of the cases have been found in sub-Saharan African 
countries, especially in East Africa. In Humera (in 
northwest Ethiopia), the proportion of VL patients co-
infected with HIV increased from 18.5% in 1998–99 
to 40% in 2006 [113]. 
VL in HIV patients has atypical clinical 
presentation; only 75% of HIV-infected patients, as 
opposed to 95% of non-HIV-infected patients, exhibit 
the characteristic clinical pattern – namely, fever, 
splenomegaly, hepatomegaly, and gastrointestinal 
involvement [114-117]. The diagnostic principles 
remain the same as those for non-HIV-infected 
patients. The presence of Leishmania amastigotes in 
the bone marrow can often be demonstrated in buffy 
coat preparation and in unusual locations (stomach, 
colon, or lungs) [118], but it has lower sensitivity in 
VL-HIV patients. 
For HIV patients, the sensitivity of antibody-based 
immunological tests such as the IFA test and ELISA is 
low. Serological tests have limited diagnostic value 
because over 40% of co-infected individuals have no 
detectable specific antibody levels against Leishmania 
[119]. In their meta-analysis, Cota et al. [73] 
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summarized the accuracy of different serological 
techniques used for diagnosing HIV-co-infected 
persons. The estimated sensitivities using random 
effect models and their respective 95% confidence 
intervals for the other tests were: IFA test, 51%; 
ELISA, 66% (40% to 88%); DAT, 81% (61% to 
95%); and immunoblotting, 84% (75% to 91%). The 
estimated specificity using random effect models and 
their respective confidence intervals for the following 
tests were: immunoblotting, 82% (65% to 94%); 
ELISA, 90% (77% to 98%); IFA test, 93% (81% to 
99%); and DAT, 90% (66% to 100%). Thus, due to 
the low sensitivity of the serological tests for VL 
diagnosis in HIV-infected patients, at least two 
different serological tests should be used for each 
patient to increase the sensitivity of antibody detection 
[120]. The detection of polypeptide fractions of 72–75 
kDa and 123 kDa of Leishmania antigen in the urine 
of patients with VL was 96% sensitive and 100% 
specific; furthermore, these antigens were not 
detectable after three weeks of treatment, suggesting a 
good prognostic value [32]. In conclusion, serology 
should not be used to rule out a diagnosis of VL 
among HIV-infected patients; an additional specially 
recommended serological test and/or molecular or 
parasitological methods may be necessary if the results 
of serological tests are negative. 
 
Conclusions 
Leishmaniasis is a global health problem and a 
major killer in endemic countries. Recent years have 
witnessed extraordinary potential progress in 
diagnosing Leishmania infection. The main challenge 
in these trials has been to reach the gold standard test 
in order to establish effective strategic programs to 
control and eradicate the disease. There are several 
methods of laboratory diagnosis of leishmaniasis; 
these include parasite detection by microscopic 
examination, culture, or molecular biology-based 
assays for detecting parasite DNA (PCR). The 
molecular tests are more sensitive than microscopic 
examination and parasite culture, but they remain 
restricted to referral hospitals and research centers. It 
could be concluded from previous studies that 
serological diagnosis is an alternative tool to the 
invasive methods of parasitological diagnosis for 
large-scale and decentralized diagnosis of 
leishmaniasis, especially VL. These serodiagnostic 
techniques are, however, of limited use for CL and 
MCL because of low sensitivity and variable 
specificity. Serologic diagnosis of VL can be 
accomplished with many techniques, such as IFA, 
ELISA, western blot, rapid strip testing for rK39 
antigen (IC), DAT, or detection of Leishmania antigen 
in urine by latex agglutination (KAtex).  
Selection of the serological test during diagnosis 
should be based on different parameters such as 
region, cost, sensitivity, specificity, feasibility, 
sustainability, and field applicability, especially in 
problematic endemic areas. Detection of antibody 
responses to parasite antigens has inherent limitations. 
First, high serum antibody levels are present in both 
asymptomatic and active VL. Second, serum anti-
Leishmania antibodies remain present for several years 
and complicate the diagnosis of relapse. Third, the 
specificity of these tests in VL-endemic areas is 
variable because there are a number of individuals 
with no clinical VL who have antileishmanial 
antibodies, complicating this specificity. Additional 
challenges originate from Leishmania/HIV co-
infection, as the co-infection may appear without the 
typical clinical signs. The immunosuppressive action 
of Leishmania/HIV co-infection makes the serological 
approach to diagnosis especially challenging. 
However, DAT, immunoblotting, and the latex 
agglutination test (KAtex) have been proven to be 
superior in diagnosis of these co-infection cases. 
Negative results of serology should not reliably 
exclude a diagnosis of VL among HIV-infected 
patients. An additional molecular or other serological 
or parasitological test may be necessary to reach an 
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